Edwards Lifesciences Corporation
EW · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $44,247,731 | $46,260,875 | $46,183,590 | $80,748,515 |
| - Cash | $3,045,200 | $1,132,300 | $769,000 | $862,800 |
| + Debt | $700,000 | $685,100 | $691,300 | $690,300 |
| Enterprise Value | $41,902,531 | $45,813,675 | $46,105,890 | $80,576,015 |
| Revenue | $5,439,500 | $5,010,000 | $5,382,400 | $5,232,500 |
| % Growth | 8.6% | -6.9% | 2.9% | – |
| Gross Profit | $4,322,000 | $3,972,700 | $4,215,200 | $4,006,600 |
| % Margin | 79.5% | 79.3% | 78.3% | 76.6% |
| EBITDA | $1,723,100 | $1,534,900 | $1,960,400 | $1,890,100 |
| % Margin | 31.7% | 30.6% | 36.4% | 36.1% |
| Net Income | $4,174,600 | $1,402,400 | $1,521,900 | $1,503,100 |
| % Margin | 76.7% | 28% | 28.3% | 28.7% |
| EPS Diluted | 6.97 | 2.3 | 2.44 | 2.38 |
| % Growth | 203% | -5.7% | 2.5% | – |
| Operating Cash Flow | $542,300 | $895,800 | $1,218,200 | $1,732,100 |
| Capital Expenditures | -$252,400 | -$266,300 | -$264,800 | -$329,800 |
| Free Cash Flow | $289,900 | $629,500 | $953,400 | $1,402,300 |